Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net ...

Game Changer Wrestling held its GCW Japan event at Tokyo Square. The event aired on TrillerTV+. Full results and highlights ...

Takeda, coming off a high of 2024 growth, is pushing through what it says will be the worst of its Vyvanse-related declines.

Teva’s chief drug Austedo—approved in Huntington’s disease and tardive dyskinesia—grew sales 19% to $498 million for the ...

From women’s wellness to chronic condition care, pharma brands are finally waking up to Reddit’s power as a go-to hub for ...

New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far ...

Takeda Pharmaceutical's net profit climbed 30% in the latest quarter, supported by stronger operating profit on lower impairment and restructuring expenses.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Takeda ( TOKYO:4502/NYSE:TAK ) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting ...

Analysts are estimating that Takeda Pharmaceutical will report an earnings per share (EPS) of $0.47. The market awaits Takeda Pharmaceutical's announcement, with hopes high for news of surpassing ...

The FDA granted 510(k) clearance to two devices, HyHub and HyHub Duo, that act as docking stations for dual vial units to ...

NET PROFIT FORECAST: Takeda's net profit is expected to have declined 0.4% from a year earlier to 94.89 billion yen, equivalent to $642.6 million, for the three months ended June 30, according to a ...